WA-PARSE-BIOSCIENCES
16.5.2023 14:01:35 CEST | Business Wire | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Israel-based Ornat Biochemicals and Laboratory Equipment to extend Parse’s reach in the Middle East.
“The past year has represented a considerable leap forward for Parse, with demand growing significantly for our Evercode single cell sequencing solutions,” noted Parse CEO and co-founder Alex Rosenberg, Ph.D. “Partnering with a premier distributor in the Middle East positions us well in the region for continued growth.”
Parse’s agreement with Ornat will give researchers in Israel access to its full single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, and the Parse Biosciences data analysis solution. The agreement bolsters Parse’s plan to offer its products in key international markets.
“Parse is accelerating the pace of single cell research with its Evercode technology. We're elated to partner with them to introduce this state of the art technology to the thriving biotech community in Israel,” said Ornat CEO, Eyal Lev.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by nearly 1,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Responding to Customer Demand, Starlink High-Speed Connectivity Now Available as an Aftermarket Option on the Cessna Citation Ascend; 560XL Series Achieves EASA Certification21.4.2026 14:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced at AERO Friedrichshafen the availability of Starlink highspeed connectivity as an aftermarket upgrade for the Cessna Citation Ascend, the newest aircraft in the bestselling Cessna Citation 560XL series, following the Federal Aviation Administration’s issuance of AeroMech’s Supplemental Type Certificate (STC). In addition, the Cessna Citation 560 XL fleet — including the XLS Gen 2, XLS+, XLS and Excel — has received European Union Aviation Safety Agency (EASA) certification for Starlink installation at Textron Aviation’s European service centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420017406/en/ Responding to customer demand, Starlink high-speed connectivity now available as an Aftermarket option on the Cessna Citation Ascend; 560XL series achieves EASA certification AeroMech’s STC utilizes Starlink’s high-speed internet technology connec
Moody’s Advances Decision-Grade Credit Intelligence Across Enterprise AI Workflows, Powered by Microsoft 365 Copilot21.4.2026 14:00:00 CEST | Press release
Moody’s decision-grade intelligence now available directly in the AI-powered tools where market participants work Moody’s Corporation (NYSE: MCO) today announced the next phase of its strategic partnership with Microsoft, integrating Moody’s decision-grade intelligence directly into Microsoft AI solutions. The milestone expands the collaboration from co-innovation to scaled, workflow-embedded distribution of Moody’s decision-grade intelligence across the enterprise environments where its customers work every day. “For over 115 years, Moody’s has served as the intelligence layer that financial professionals turn to when making consequential decisions,” said Rob Fauber, President and Chief Executive Officer of Moody’s. “By embedding that intelligence directly into Microsoft’s AI solutions at enterprise scale, we’re making decision-grade analysis available not just to specialists, but to every person across an organization who needs it.” The integrations operate across two channels. Using
Redslim expands its global footprint into Latin America21.4.2026 14:00:00 CEST | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Latin America (LATAM) region, marking the next step in its growth strategy to support multinational brands and retailers across every major market. Following its recent expansion into APAC, this move reinforces Redslim’s momentum in building a truly global presence, reflecting growing demands from international clients for a trusted partner delivering reliable and AI-ready data and insights at scale. The expansion includes the appointment of Alejandro Merlo as Regional Director and Javier Gonzalez as Regional Manager for the region. Latin America represents a strong growth opportunity for global consumer brands, but also one of the most complex data environments. Rapid digital adoption and shifting consumer behaviours are driving demand for reliable market intelligence, while fragmented retailer structures and country-specific data landscapes make consis
Adtran’s SDG router portfolio receives FCC conditional approval, supporting ongoing broadband expansion21.4.2026 14:00:00 CEST | Press release
News summary: FCC approval exempts Adtran’s SDG router portfolio from Covered List restrictions through October 1, 2027 Decision enables uninterrupted shipments, authorizations and deployments across current and next-generation SDG platforms Regulatory clarity supports long-term SDG investment and rollout planning Adtran today announced that its service delivery gateway (SDG) carrier-grade router portfolio has received conditional approval from the FCC’s Public Safety and Homeland Security Bureau, formally exempting the platforms from FCC Covered List restrictions through October 1, 2027. The decision places Adtran among the first router manufacturers to achieve this designation under the FCC’s national security review process. By ensuring continued access to Adtran’s SDG technology, the approval enables service providers to maintain deployment momentum, reduce operational risk and invest confidently in the long-term expansion of broadband networks while navigating evolving regulatory
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs21.4.2026 14:00:00 CEST | Press release
Partnership enables timely access to botensilimab plus balstilimab through France’s government-reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named-patient programs (NPP) in select countries Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus’ global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421146539/en/ The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Effective immediately, BAP Pharma will serve as Agenus’ exclusive partner for the coordination of BOT+BAL global access program operations, including program requests, case coordination, distribution logistics, and re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom